Lexeo Therapeutics (LXEO) Accounts Payables (2022 - 2026)

Lexeo Therapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 72.16% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 72.16% YoY), while the FY2025 annual figure was $4.9 million, down 24.33% from the prior year.
• Accounts Payables came in at $3.3 million for Q1 2026 at Lexeo Therapeutics, down from $4.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $20.0 million in Q2 2025 to a low of $2.7 million in Q3 2023.
• A 5-year average of $6.6 million and a median of $4.8 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 247.35% in 2025 and plunged 72.16% in 2026, its largest moves.
• Lexeo Therapeutics' Accounts Payables stood at $2.7 million in 2022, then surged by 41.67% to $3.8 million in 2023, then soared by 69.14% to $6.4 million in 2024, then declined by 24.33% to $4.9 million in 2025, then sank by 31.32% to $3.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $3.3 million, $4.9 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison